Cell Viability Assays Market

Growing adoption for drug discovery is driving the market growth

The growing use of cell viability assays for the discovery of drugs is driving Market CAGR for Cell Viability Assays. The existence of living or viable cells is referred to as cell viability, and it is thought to be a sign of good cell health. Viability levels are frequently altered in studies as a result of the action of chemical or physical agents, as in toxicity experiments. Cell viability assays (CVAs) are widely utilized in the pharmaceutical and healthcare sectors because they can be used to assess how cells would react to any pathogenic agent or medication.

Cell viability assays are becoming more often used in drug discovery and treatment programs as a result of the COVID-19 pandemic. For instance, Calidi Biotherapeutics Inc. declared in August 2020 that Personalized Stem Cells, Inc.'s IND (investigational new drug) application had been approved by the US FDA. The IND that was submitted was for the use of stem cells in the treatment of individuals with COVID-19 and pneumonia.

Therefore, the usage of cell viability assay for understanding the reaction of living cells and viability for any line of treatment has been greatly ignited by the rise in cellular-based therapies for the treatment of Covid-19 infection.

The development of cell-based medicines is receiving more attention, which is propelling market expansion. Industry development is being aided by rising FDA approvals, scientific trials, and strategic activities like partnerships between important market participants. For instance, the FDA approved Abecma (idecabtagene vicleucel), in March 2021. In addition, CRISPR Therapeutics and ViaCyte, Inc. reported in February 2022 that the Phase 1 trial for a new gene-edited treatment for Type 1 Diabetes had dosed its first patient. These activities are anticipated to fuel industry expansion during the anticipated years

Additionally, increasing financing for stem cell research from various governments and industry participants is projected to create new market expansion prospects. For instance, the Federal Minister for Health and Aged Care, Hon. Greg Hunt, provided money totaling USD 18 million to the 2020 Stem Cell Mission in June 2021. The motive is to enhance health outcomes through the development and delivery of new, safe, and efficient stem cell treatments. Additionally, Curi Bio obtained investment in the amount of USD 10 million in January 2022 for a drug discovery platform that focuses on stem cells.

Therefore, it is anticipated that the market will be driven during the study period by the growing emphasis on stem cell research. Thus, driving the Cell Viability Assays market revenue.

The Global Cell Viability Assays Market Industry is projected to experience substantial growth in the coming years. With a market value expected to reach 2.24 USD Billion in 2024 and further expand to 5.48 USD Billion by 2035, the industry demonstrates a promising trajectory. The anticipated CAGR of 8.47% from 2025 to 2035 indicates a robust demand for cell viability assays across various applications, including drug discovery, toxicology, and cancer research. This growth is likely driven by advancements in technology, increasing research activities, and the rising prevalence of chronic diseases, positioning the market for significant expansion.

The Global Cell Viability Assays Market Industry experiences a surge in demand driven by the increasing need for drug discovery and development. Pharmaceutical companies are investing heavily in research and development, leading to a projected market value of 2.24 USD Billion in 2024. This growth is attributed to the necessity for effective screening methods to evaluate drug efficacy and toxicity. As the industry evolves, cell viability assays are becoming integral in identifying potential drug candidates, thereby enhancing the overall efficiency of the drug development process. The focus on personalized medicine further amplifies the demand for these assays, suggesting a robust future for the market.

The rising prevalence of chronic diseases globally is a critical driver for the Global Cell Viability Assays Market Industry. As conditions such as cancer, diabetes, and cardiovascular diseases become more common, there is an urgent need for effective therapeutic interventions. Cell viability assays play a crucial role in understanding disease mechanisms and evaluating treatment responses. This growing health concern is anticipated to contribute to the market's expansion, with projections indicating a market size of 5.48 USD Billion by 2035. The increasing focus on research related to chronic diseases underscores the importance of cell viability assays in developing targeted therapies.

Technological innovations are significantly influencing the Global Cell Viability Assays Market Industry. The introduction of high-throughput screening technologies and automated systems enhances the accuracy and efficiency of cell viability assessments. These advancements allow researchers to conduct large-scale experiments with minimal human error, thereby expediting the research process. The market is expected to grow at a CAGR of 8.47% from 2025 to 2035, indicating a strong trajectory fueled by these innovations. Moreover, the integration of artificial intelligence in assay development is likely to further streamline processes, making cell viability assays more accessible and reliable for researchers worldwide.

Regulatory bodies are increasingly supporting research and development initiatives, which positively impacts the Global Cell Viability Assays Market Industry. Governments are recognizing the importance of advancing scientific research, leading to funding opportunities and grants for innovative projects. This support encourages the development of new cell viability assays that meet regulatory standards, thereby enhancing their adoption in laboratories. The emphasis on compliance with safety and efficacy regulations is likely to drive the demand for these assays, as researchers seek reliable methods to validate their findings. This regulatory environment fosters a conducive atmosphere for growth in the cell viability assays market.

The expansion of the biotechnology and pharmaceutical sectors is a significant driver for the Global Cell Viability Assays Market Industry. As these sectors continue to grow, there is an increasing demand for reliable and efficient cell viability testing methods. Biotech firms are increasingly utilizing these assays to validate their research findings and ensure the safety and efficacy of their products. This trend is expected to propel the market forward, with a notable increase in investments directed towards assay development. The collaboration between academic institutions and industry players is likely to foster innovation, further enhancing the relevance of cell viability assays in drug development and research.

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. During the projected period, the North American Cell Viability Assays market is expected to dominate over the course of the forecasted period. This significant increase in investment initiatives by the government, the rise in the prevalence of chronic diseases like cancer, and the presence of a top-notch infrastructure for clinical and laboratory research in North America are all factors that contribute to this significant share.

Further, the major countries studied in the market report are The US, Canada, German, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  CELL VIABILITY ASSAYS MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Asia Pacific Cell Viability Assays market accounts for the fastest market share due to the increased regional need for innovative medicines. Other elements promoting regional prosperity include escalating government expenditure in R&D and quickening infrastructure growth. Moreover, the China market of Cell Viability Assays held the largest market share, and the India market of Cell Viability Assays was the quickest-growing market in the Asia-Pacific region.

The Europe Cell Viability Assays Market is expected to expand at the quickest CAGR from 2023 to 2032. This is due to the expansion of stem cell research, the growing demand for early and precise identification of chronic diseases, and the availability of well-established clinical and healthcare infrastructure in the area. Further, the Canada market of Cell Viability Assays was the fastest-growing region in the market, and the German market of Cell Viability Assays held a substantial share of the market.

Leading market players are investing capital and resources across research and development to extend their product offerings, this is expected to help the Cell Viability Assays market, grow even more. Market leaders and manufacturers are also adopting various strategies to expand their worldwide footprint, with important market developments including new product developments & launches, contracts & agreements, mergers & acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Cell Viability Assays industry must offer cost-effective items.

The manufacturers are making use of locally available resources to minimize the production costs which will aid the growth of the  Cell Viability Assays industry to benefit clients and increase the market sector. In recent years, the Cell Viability Assays industry has offered some of the most significant advantages to medicine. Major players in the Cell Viability Assays Market, including Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, GE Healthcare, Danaher Corporation, Becton Dickinson & Company, Promega Corporation, Biotium, Abcam plc, Creative Bioarray, and others, are attempting to increase market demand by investing in research and development operations.

A manufacturer and distributor of medical equipment, reagents, and instruments is Becton Dickinson and Co. (BD). Syringes and pen needles, intravenous catheters, infusion pumps, disposables, automated medication dispensing, and supply management systems, pre-fillable drug delivery systems, respiratory ventilation and diagnostic equipment and consumables, items for the secure collection and transportation of diagnostic specimens, instruments and reagent systems to detect a variety of infectious diseases and cancers, and clinical research tools are among its main products. Researchers working in the field of life sciences, hospitals, clinics, the pharmaceutical sector, and the general public can all benefit from BD's products.

In February 2022, A privately held company with its headquarters in Salamanca, Spain, Cytognos specializes in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection, and immune monitoring research for blood diseases. Today, BD, a leading  medical technology company, announced that it has successfully acquired Cytognos.

GE Healthcare Technologies Inc. (GE HealthCare) is a leading  provider of medical devices, specializing in the design, development, production, and distribution of diagnostic imaging, clinical systems, drug discovery, biopharmaceutical production, cellular technologies, imaging agents for use in medical scanning, and a variety of healthcare IT products. Additionally, GE HealthCare offers services including computerized data management, performance enhancement, performance solutions, and remote diagnosis and repair services for medical devices made by the business and others.

In June 2021, GE Healthcare presented new molecular imaging products and solutions at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 summer conference, along with new chances to increase reach to radioactive tracers & pharmaceutical imaging agents.